{
    "clinical_study": {
        "@rank": "80696", 
        "arm_group": [
            {
                "arm_group_label": "Once daily", 
                "arm_group_type": "Experimental", 
                "description": "Nifedipine 12 mg Once daily"
            }, 
            {
                "arm_group_label": "Twice Daily", 
                "arm_group_type": "Experimental", 
                "description": "Nifedipine 12 mg twice daily"
            }
        ], 
        "brief_summary": {
            "textblock": "This is an open label study. The study will consist of 2 treatment group: coated Nifedipine\n      suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated\n      Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).\n      Approximately 30 subjects will participate into this 8-week study. The primary objective is\n      to examine the dose effect of coated Nifedipine suppository on Anal fissure pain and\n      healing."
        }, 
        "brief_title": "An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing", 
        "condition": "Anal Fissure", 
        "condition_browse": {
            "mesh_term": "Fissure in Ano"
        }, 
        "detailed_description": {
            "textblock": "This is an open label study. The study will consist of 2 treatment group: coated Nifedipine\n      suppository containing 12 mg of Nifedipine applied twice daily (group 1) and coated\n      Nifedipine suppository containing 12 mg of Nifedipine applied once daily (group 2).\n      Approximately 30 subjects will participate into this 8-week study. A screening visit will be\n      used to determine subject suitability for inclusion in the trial. Within one week of the\n      screening visit, subjects who meet all inclusion criteria and none of the exclusion criteria\n      will receive Coated Nifedipine 12 mg Suppository X2 a day (BID) (24 mg/day total) OR  Coated\n      Nifedipine 12 mg Suppository X1 a day (OD) (12 mg/day total) for a period of 8 weeks.\n      During this period, 4 study visits (at 0, 2, 5,  and 8 weeks) will take place. Study\n      medication will be administered BID (in the morning and in the evening) or OD (only in the\n      morning). In addition to receiving study medication, subjects will be maintained on a\n      standard treatment for Anal Fissure: sitz baths, high fiber diet."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Single anal fissure\n\n          -  Signed written informed consent;\n\n          -  Male or female subjects 18 to 65 years of age;\n\n          -  Has chronic anal fissure defined as history of anal pain at least three days a week\n             for 30 days duration or more\n\n          -  Visible fibers of the internal sphincter were seen at the base of the fissure or if a\n             sentinel pile was present.\n\n          -  VAS of > 35 mm in screening visit\n\n          -  If female, is nonlactating, has a negative urine pregnancy test result, and does not\n             plan on becoming pregnant during the study, or not of childbearing potential\n             (hysterectomy or tubal ligation at least 6 months prior to entery to the study or\n             post-menopausal for 1 year); if of childbearing potential (including peri-menopausal\n             women who have had a menstrual period within one year) must practice or be willing to\n             continue to practice appropriate birth control (such as implants, injectables, oral\n             contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal\n             ligation, or a vasectomized partner) during the entire study duration.\n\n        Exclusion Criteria:\n\n          -  Known allergy to Nifedipine, polyethylene-glycol, propylene Glycol or silicone.\n\n          -  Fissure resulting from inflammatory bowel disease, venereal disease, perianal\n             psoriasis, immunodeficiency syndrome.\n\n          -  Anal abscess\n\n          -  Fixed anal stenosis\n\n          -  Active or past history of cardiovascular or cerebrovascular disease including\n             unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically\n             significant arrhythmia, moderate to severe  congestive heart failure, or cardiac\n             valve abnormalities;\n\n          -  Type 1 diabetes mellitus;\n\n          -  Insulin treated type 2 diabetes mellitus;\n\n          -  History of Renal insufficiency.\n\n          -  History of Liver insufficiency.\n\n          -  Malignant disease within 5 years of screening;\n\n          -  Has uncontrolled hypertension (sitting blood pressure <160/95 mmHg at screening)\n\n          -  History of chronic gastrointestinal disease.\n\n          -  History of rectal surgery.\n\n          -  History of gastrointestinal surgery.\n\n          -  History of HIV, hepatitis B, hepatitis C.\n\n          -  In need of chronic use of medication, with the exception of birth control\n             medications.\n\n          -  Currently uses medication for acute illness (other than medications for use of\n             treatment/pain relief of anal fissure).\n\n          -  Has used, in the last two weeks, drugs that may affect blood coagulation, such as\n             Aspirin at a dose higher than 500 mg/day , Warfarin, Sintrom, Enoxaparin, Nadroparin,\n             Heparin,  Clopidogrel, Ticlopidine.\n\n          -  Is using drug that may affect rectal tone:\n\n          -  Calcium Channel Blocker such as:\n\n               -  Nifedipine (Osmo-Adlat, Pressolat, Nifedipine -Teva, Nifedilong)\n\n               -  Amlodipine (Amlow,  Norvasc, Amlodipine-Teva)\n\n               -  Lercadipine (Vasodip)\n\n               -  Verapamil (Ikacor, Ikapress, Verapress)\n\n               -  Felodipine (Penedil)\n\n               -  Diltiazem (Adizem, Dilatam)\n\n          -  Nitrate donors such as:\n\n               -  Glyceryl Trinitrate (Deponit)\n\n               -  Isosorbid dinitrate (Isoket, Isolong)\n\n               -  Isosrbid mononitrate (Monocord, Monolong, Mononit)\n\n               -  Nitroglcerine (Nitrocine, Nitroderm, Nitrolingual)\n\n          -  Has upon physical examination a rectal deformation or signs of rectal disease such as\n             bleeding hemorrhoids, fistula. infection or space occupying lesion.\n\n          -  Is an immediate family member of personnel directly affiliated with the study at the\n             investigative site, or is personally directly affiliated with the study at the\n             investigative site; or\n\n          -  Is employed by RDD Pharma Ltd."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023047", 
            "org_study_id": "RDD 112"
        }, 
        "intervention": {
            "arm_group_label": [
                "Once daily", 
                "Twice Daily"
            ], 
            "intervention_name": "Nifedipine 12 mg coated suppositories", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nifedipine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Anal Fissure", 
            "Nifedipine"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "contact": {
                    "email": "walfisch@bgu.ac.il", 
                    "last_name": "Shlomo Walfisch, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Beer Sheba", 
                        "country": "Israel", 
                        "state": "Negev"
                    }, 
                    "name": "Macabi outpatient clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "natanp59@gmail.com", 
                    "last_name": "Natan Polokshot, MD", 
                    "phone": "972577346185"
                }, 
                "facility": {
                    "address": {
                        "city": "Rehovot", 
                        "country": "Israel"
                    }, 
                    "name": "Macabi outpatient clinic"
                }, 
                "investigator": {
                    "last_name": "Natan Polokshot, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "skyzer@laniado.org.il", 
                    "last_name": "Shlomo Keizer, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Tel Aviv", 
                        "country": "Israel"
                    }, 
                    "name": "Macabi HMO outpatient clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dryziv@gmail.com", 
                    "last_name": "Yehiel Ziv, MD", 
                    "phone": "972522595876"
                }, 
                "facility": {
                    "address": {
                        "city": "Zrifin", 
                        "country": "Israel"
                    }, 
                    "name": "Asaf Harofe Hospital"
                }, 
                "investigator": {
                    "last_name": "Yehiel Ziv, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Israel"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing", 
        "overall_contact": {
            "last_name": "Merav Kohelet", 
            "phone": "0508463418"
        }, 
        "overall_contact_backup": {
            "email": "barak@rddpharma.com", 
            "last_name": "Nir Barak", 
            "phone": "035114148"
        }, 
        "overall_official": {
            "affiliation": "RDD Pharma Ltd", 
            "last_name": "Nir Barak, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Israel: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To examine the effect of coated Nifedipine suppository on Anal fissure pain as measured by Visual Analog Score", 
            "safety_issue": "No", 
            "time_frame": "8 weeks after study initiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023047"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "safety will be assessed by the number of participants with adverse events. Tolerability will be assessed by the number of participants that discontinue treatment.", 
            "measure": "To investigate the Safety and tolerability of coated Nifedipine suppositories in Anal Fissure patients .", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "source": "RDD Pharma Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "RDD Pharma Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}